Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News.
Krazati had received accelerated approval in 2024 in this setting. But a Phase …
Verastem Oncology has launched a marketing campaign for its co-packaged cancer drugs to drive use of the treatment in earlier lines of therapy.
In its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral
A powerful spending committee in Congress wants the FDA to ban the use of clinical trial data from China in future applications by drugmakers to
A federal judge has dismissed part of Eli Lilly’s lawsuit alleging Empower Pharmacy misled customers about its compounded versions of the obesity drug tirzepatide. But
WASHINGTON — Supreme Court justices gave a few hints about how they intend to rule in a divisive case for the pharmaceutical industry. In its
Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News.
Krazati had received accelerated approval in 2024 in this setting. But a Phase …